Fig. 7
Myricetin blocks the interaction of SEVI with HIV-1 virions. SEVI samples (200 μg/ml) were first incubated with graded concentrations of myricetin for 30 min. The samples were then centrifuged at 12,000 rpm for 5 min; the supernatant was removed, and the pellets were resuspended and mixed with HIV-1SF162 (a) and HIV-1NL4-3 (b). These mixtures were centrifuged, and the p24 antigens present in the pellet were evaluated using a p24-antigen ELISA. c The zeta potential of SEVI fibrils in the presence or absence of myricetin was measured using Zeta Nanosizer. Average values (± SD) were calculated from triplicate measurements; the data shown represent one representative trial of three independent experiments. One-way ANOVA with Dunnett’s post hoc multiple comparisons test was used to statistically analyze the differences between samples containing SEVI alone and samples containing SEVI and myricetin (*p < 0.05; **p < 0.01, ***p < 0.001)